In fact, AZD4547 has demonstrated anti-most cancers exercise in Section II/III clinical trials focusing on the regression of breast and gastric tumors30. Because AZD4547 targets a broader array of FGFRs, the risk of acquiring drug resistance by way of option signaling by other FGFRs is minimized. Even so, Regardless of https://vonu752lru6.wikidirective.com/user